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Purpose. To develop a clinically viablemathematicalmodel that quantitatively predicts tumor volume change during radiotherapy in
order to provide treatment response assessment for prognosis, treatment plan optimization, and adaptation.Method andMaterials.
The correction factors containing hypoxia, DNA single strand breaks, potentially lethal damage, and other factors were used to
develop an improved cell survivalmodel based on the popular linear-quadraticmodel of cell survival in radiotherapy.The four-level
cell populationmodel proposed byChvetsov et al. was further simplified by removing the initial hypoxic fraction and reoxygenation
parameter, which are hard to obtain in routine clinics, such that an easy-to-use model can be developed for clinical applications.
The newmodel was validated with data of nine lung and cervical cancer patients. Results. Out of the nine cases, the new model can
predict tumor volume change in six cases with a correlation index R2 greater than 0.9 and the rest of three with R2 greater than 0.85.
Conclusion. Based on a four-level cell population model, a more practical and simplified cell survival curve was proposed to model
the tumor volume changes during radiotherapy. Validation study with patient data demonstrated feasibility and clinical usefulness
of the new model in predicting tumor volume change in radiotherapy.
1. Introduction
As the information from posttherapy imaging usually comes
too late to realistically impact patient management, early
prediction of therapy outcome is of paramount importance
[1, 2]. Many literatures have confirmed that therapy-induced
tumor volume changes can be used to predict ultimate
local tumor control and patient survival [1–3]. This leads to
increased research interests in monitoring response of the
tumor volume to radiotherapy.
A substantial number of mathematical models for the
analysis of the tumor volume change have been developed
based on clinical data and the linear-quadratic (LQ) model.
These models span from simple tumor-volume models sim-
ilar to those proposed by Fischer [4–6] to more complicated
computer implementations that are based on 3D individual
cell simulations using random processes simulated with
Monte Carlo methods [7, 8]. But they do not use underlying
radiobiologic mechanisms [9].
As the development of functional and molecular imag-
ing techniques and equipment over recent years, such as
functional magnetic resonance imaging (fMRI) and positron
emission tomography (PET), radiobiologic tumor regression
models have been studied. The four-level population model
proposed by Chvetsov et al. combines cell hypoxia, reoxy-
genation, proliferation, disintegration, and other radiobio-
logic phenomena, which shows meaningful breakthrough
andmore innovation than previous studies [9].These approx-
imations improve accuracy of themodel. But they are difficult
to be used in clinical settings. For instance, measurements
of initial hypoxic fraction and reoxygenation rate of tumors
have not been implemented in clinical cancer management
because of the high cost burden on patients.
Improvement to the LG model is needed to extend its
applicability in radiobiology studies.Wang et al. reported that
the model took into account only the repair process, whereas
the reduction of sublethal lesions owing to conversion to
lethal lesions with further radiation had been ignored. This
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is acceptable in low fraction dose and low-dose rate (LDR)
irradiation; however, it could lead to large discrepancies in
high fraction dose and high-dose rate (HDR) irradiation [4].
Therefore, an improved cell survival model based on
the conventional LQ model and simplified cell population
model is needed to promote the development of personalized
therapy. The aim of this paper is to develop a clinically
viablemathematical model that quantitatively predicts tumor
volume change during radiotherapy in order to provide
treatment response assessment for prognosis, treatment plan
optimization, and adaptation.
2. Methods and Materials
2.1. Cell Survival Curve. According to the linear-quadratic
model in radiation biology, the average number of DNA
double strand breaks (N) by ionizing radiation in a single cell
is assumed to be a linear-quadratic function of radiation dose
(𝐷) as shown in the following:
𝑁 = 𝛼 × 𝐷 + 𝛽 × 𝐷
2
. (1)
It assumes that there are “two” components involved in
cell killing: the linear component (𝛼), which characterizes
a single lethal event made by one track action, and the
quadratic component (𝛽), which characterizes the accumu-
lation of sublethal events made by two-track action [10]. As
such, the conventional cell survival curve can be expressed
by the following [11, 12]:
𝑆 = 𝑒
−𝑁
= 𝑒
−(𝛼𝐷+𝛽𝐷
2
)
. (2)
However, this cell survival equation is based on series
of hypotheses and assumptions, which do not reflect and
explicate all events of DNA damage induced by ionization.
(1) Both types of events describe the DNA double strand
breaks, whereas the damage caused by theDNA single
strand breaks has been ignored. Studies confirmed
that X-ray induced base damage and single-strand
damage that are far more than the number of double-
strand damage, often 50 times more, and, under
certain conditions, the DNA single-strand damage
can be converted into double-strand damage resulting
in the stop of cell proliferation [11].
(2) The definition of reproductive death is the loss of
the capacity for sustained proliferation, that is, the
loss of reproductive integrity.This definition reflects a
narrow view of radiobiology. A cell may be physically
present and apparently intact, may be able to make
proteins or synthesize DNA, and may even be able to
struggle through one or two mitoses, but if it has lost
the capacity to divide indefinitely and produce a large
number of progeny, it is by definition dead [11, 12].
However, this kind of tumor cells and their colonies,
which may have a large impact with their portion
increasing continuously during treatment, have not
been taken into account when calculating the tumor
volume.
Table 1: Initial tumor volume (𝑉
0
) and volume halving time (𝑇
1/2
).
(a) Lung cancer cases
Patient serial number Mean value
1 2 3 4
𝑉
0
/(cm3) 7.6 27.4 97.7 189.3 80.5
𝑇
1/2
/(day) 42.5 35.9 50.2 33.3 40.5
(b) Cervical cancer cases
Patient serial number Mean value
1 2 3 4 5
𝑉
0
/(cm3) 8.0 14.2 22.1 76.1 375.2 99.1
𝑇
1/2
/(day) 13.9 90.6 15.6 24.4 31.0 35.1
(3) Radiation exposure can alter the environment sur-
rounding cells so that cells may be potentially lethal
damaged (PLD). It has been suggested that capability
of PLD repair plays an important role in the resistance
to treatment for human cancers. Such that, cell sur-
vival ratio may be increased to exceed or be reduced
to less than the nominal value by the effect of specific
dose.Therefore, the overall level of𝑁will be affected.
(4) Researchers have found that the cell’s oxygen and
blood supply have an impact on the tumor radiosen-
sitivity. So, the microenvironment of cancer cells will
affect the overall level of𝑁.
To take these factors into account, we proposed two
correction factors, 𝐴 and 𝐵, to make an improvement to the
cell survival model. The new model is defined as
𝑆 = 𝑒
−𝐴×(𝛼𝐷+𝛽𝐷
2
)+𝐵
, (3)
where 𝐴 represents a variety of undefined factors related to
cancer staging, histological grade, oxygen supply, blood flow,
and the living environment after irradiation B represents the
impact caused by the events that are not included in 𝛼 and 𝛽
events, such as DNA single strand break and cell proliferation
before reproductive death.
This modification takes more cancer-specific factors into
account and enables a better expression to the real situation.
In addition, cell hypoxia factor is also taken into account,
which lays a foundation for the simplification of the four-level
cell population model which will be presented in the next
section.
2.2. Model of Tumor Volume Change. The four-level popula-
tion model proposed by Chvetsov et al. is one of the com-
prehensive models. But the measurement of initial hypoxic
fraction and reoxygenation rate of the tumor makes it
difficult for clinical application. So we considered simplifing
the model by transferring the initial hypoxic fraction and
reoxygenation parameter to the improved cell survival curve,
such that an easy-to-use model can be developed for clinical
applications.
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Figure 1: Correlation coefficients of the models: diamonds: 𝑅2; triangles: 𝑅2
0
; dash lines: mean values. (a) Lung cancer cases, with mean value
of 0.94 for 𝑅2 and 0.63 for 𝑅2
0
, respectively; (b) cervical cancer cases, with mean value of 0.93 for 𝑅2 and 0.87 for 𝑅2
0
, respectively.
Table 2: Results of the model validation experiments.
(a) Lung cancer cases
Patient serial number
1 2 3 4
𝐴 0.85 0.82 0.66 0.82
𝐵 −2.03 −2.10 −2.01 −0.41
𝑅
2 0.99 0.89 0.91 0.97
𝑅
2
0
0.52 0.43 −0.68 0.94
(b) Cervical cancer cases
Patient serial number
1 2 3 4 5
𝐴 0.43 0.19 0.24 0.74 0.17
𝐵 −1.66 −2.95 −1.78 −0.71 −0.63
𝑅
2 0.99 0.87 0.99 0.95 0.87
𝑅
2
0
0.92 −1.43 0.87 0.81 0.87
The tumor volume (𝑉) is assumed to be proportional to
the total number of cells in the tumor (𝑁
𝑡
); it can be evaluated
using the following equation:
𝑉 = 𝑁
𝑡
× V, (4)
where V is a constant that includes the volume of a single cell
and the volume of the related intercellular space. Radiation
will cause death of some proliferative cells. After irradiation
with dose 𝐷, the initial total number of cells in the tumor
(𝑁
𝑡,0
) is changed to
𝑁
𝑙,1
= 𝑁
𝑡,0
× 𝑆,
𝑁
𝑑,1
= 𝑁
𝑡,0
× (1 − 𝑆) .
(5)
𝑁
𝑙,1
and𝑁
𝑑,1
are the number of viable and lethally damaged
cells after first irradiation. The number of cells after the kth
dose fraction is
𝑁
𝑙,𝑘
= 𝑁
𝑙,𝑘−1
× 𝑆,
𝑁
𝑑,𝑘
= 𝑁
𝑑,𝑘−1
+ 𝑁
𝑙,𝑘−1
× (1 − 𝑆) .
(6)
During the time interval (Δ𝑡
𝑘
) between k and (𝑘+1) dose
fraction, the total number of cells in the tumor changes as
a result of the proliferation of dividing viable cells and the
disintegration of lethally damaged cells. The repopulation of
viable cells is governed by its exponential growth with the
constant 𝜆 as shown in the following:
𝜆 =
ln 2
𝑇pot
(7)
which is related to the potential doubling time (𝑇pot). The
disintegration of lethally damaged cells is modeled using the
exponential decay with the decay constant 𝜇:
𝜇 =
ln 2
𝑇
1/2
, (8)
where 𝑇
1/2
is the volume halving time.
Taking the models for proliferation and disintegration
into account, the cell number will change during the time
interval between dose fractions and can be expressed as
follows:
𝑁
𝑙,𝑘
= 𝑁
𝑙,𝑘
exp (𝜆Δ𝑡
𝑘
) ,
𝑁
𝑑,𝑘
= 𝑁
𝑑,𝑘
exp (−𝜇Δ𝑡
𝑘
) .
(9)
And the total number of cells and the tumor volume at
time of 𝑡 and after the kth dose fraction are
𝑁
𝑡,𝑘
= 𝑁
𝑑,𝑘
+ 𝑁
𝑙,𝑘
,
𝑉
𝑡,𝑘
= 𝑁
𝑡,𝑘
× V.
(10)
4 The Scientific World Journal
Patient 1 
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0 10 20 30 40 50
Times (days)
0 10 20 30 40 50
Times (days)
0 10 20 30 40 50
Times (days)
0 10 20 30 40 50
Times (days)
Patient 2
Patient 3 Patient 4
(a)
Patient 4 Patient 5
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0 10 20 30 40 50
Times (days)
0 10 20 30 40 50
Times (days)
Patient 1 Patient 2
Patient 3
0.2
0
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0.2
0.4
0.6
0.8
1
1.2
Tu
m
or
 v
ol
um
e (
%
)
0 10 20 30 40 50
Times (days)
0 10 20 30 40 50
Times (days)
0
0
10 20 30 40 50
Times (days)
(b)
Figure 2: Measured (symbols) and modeled results (solid lines) of the tumor volumes. (a) Lung cancer cases, (b) cervical cancer cases.
2.3. Model Validation. MATLAB R2010a (The Math Works,
Inc., Natick, USA) and CT image data of nine patients (four
lung cancer cases and five cervical cancer cases) were used to
validate the new model in comparison with the results from
the conventional model. The patients received radiotherapy
treatment, and three to four sequential CT image sets were
acquired on day one and in the interval of about one to
two weeks during the treatment. Tumors were delineated by
an experienced radiation oncologist on the CT images, and
volumes were calculated accordingly [13]. The initial volume
(𝑉
0
) and volume halving time (𝑇
1/2
) are listed in Table 1. The
parameter 𝑇pot was obtained from published data, for the
lung tumors 𝑇pot = 5.5 days [9] and for the cervical tumors
𝑇pot = 4.5 days [11].
The correlation index (𝑅2) was used to quantify the
goodness of fit of the models to the actual patient data. 𝑅2
is defined in the following:
𝑅
2
= 1 −
∑ (𝑦 − 𝑦)
2
∑ (𝑦 − 𝑦)
2
, (11)
where 𝑦 is the measured value, 𝑦 is the predicted value by the
model and 𝑦 is the mean of the measured data. It is generally
believed that, when 𝑅2 is greater than 0.8, a high degree of
correlation exists [14].
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3. Results and Discussion
The correlation coefficient (𝑅2), 𝐴, and 𝐵 were obtained by
using least square method. Results are shown in Table 2.
Here, 𝑅2 is the correlation coefficient between the predicted
tumor volume change by using the new simplified four-level
cell population model and the measured ones, and 𝑅2
0
is the
correlation coefficient between the predicted tumor volume
change by using the conventional model and the measured
data for comparison. Figure 2 shows the measured data and
the modeled results of the tumor volumes for the 9 cases.
From Table 2, it can be seen that the new model can
predict the tumor volume change in six of the nine cases with
correlation index 𝑅2 greater than 0.9 and the rest of three
cases with 𝑅2 greater than 0.85. When comparing the values
of 𝑅2 with 𝑅2
0
in Figure 1, it is clear that 𝑅2 is greater than
𝑅
2
0
for all the cases and the mean values of 𝑅2 is significantly
greater than the ones of 𝑅2
0
(0.94 > 0.63 for lung cancer cases
and 0.93 > 0.87 for cervical cancer cases). It is shown that
the improved cell survival model yields better prediction for
tumor volume change during the radiation treatment.
The correction factor 𝐴 is smaller than 1, which may be
due to the impact of reduced amount of the total of the DNA
double strand breaks caused by the PLD and microenviron-
ment change for the irradiated cells; for example, hypoxicmay
increase the tumor radioresistance. 𝐵 is negative for all the
cases; thismay be due to the impact from the events of neither
𝛼nor𝛽; for example, DNA single strand breakwould increase
cell reproductive death. The results have demonstrated the
advantages of the proposed tumor volume change model and
shown its feasibility and practical usefulness.
4. Conclusions
Several hard-to-get factors in clinical radiotherapy were
considered and used in the development of a new cell survival
model. The four-level cell population model was simplified
to obtain an easy-to-use model for clinical applications.
The combination of the new models contains more radio-
biological factors, which can be used to describe tumor
volume variation during the fractionated radiotherapy. As
the tumor volume changes during radiotherapy could affect
the received dose in the intensity-modulated radiotherapy
(IMRT), the new mode proposed in this study provides a
method in understanding the radiobiological processes and
potential application in improving the IMRT treatments.
It should be noted that certain limitations exist in the
new model. For instance, 𝑅2, 𝐴, and 𝐵 were obtained by
using least square method only. Future studies should take
patient age, gender, tumor location, shape, stage, degree of
differentiation, and other information into account, so that
a more comprehensive model can be developed and used to
the prediction and monitoring of the tumor volume changes
during radiotherapy.
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